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Available online 22 October 2016Expansionmutations in the C9orf72 genemay cause amyotrophic lateral sclerosis (ALS), frontotemporal demen-
tia (FTD), ormixtures of the two clinical phenotypes. Different imagingﬁndings have been described for C9orf72-
associated diseases in comparison with sporadic patients with the same phenotypes, but it is uncertain whether
different phenotypes have a common genotype-associated imaging signature. To address this question, 27 unre-
lated C9orf72 expansionmutation carriers (C9+)with varied phenotypes, 28 age-matched healthy controls and
22 patients with sporadic ALS (sALS) underwent 3T MRI scanning and clinical phenotyping. Measures of brain
volumes and cortical thickness were extracted from T1 images. Compared to healthy controls and sALS patients,
symptomatic C9+ subjects had greater ventricular volume loss and thalamic atrophy for age,with diffuse, patchy
cortical thinning. Asymptomatic carriers did not differ from controls. C9+ ALS and ALS-FTD patients had less
thinning of the motor cortex than sALS patients, but more thinning in extramotor regions, particularly in frontal
and temporal lobes. C9+ ALS patients differed from sporadic ALS patients in the thickness of the superior frontal
gyrus and lateral orbitofrontal cortex. Thickness of the precentral gyrus was weakly correlated with the revised
ALS functional rating scale. Thickness of many cortical regions, including several frontal and temporal regions,
was moderately correlated with letter ﬂuency scores. Letter ﬂuency scores were weakly correlated with ventric-
ular and thalamic volume. To better understand how imaging ﬁndings are related to disease progression, nine-
teen C9+ subjects and 23 healthy controls were scanned approximately 6 months later. Ventricular volume
increased in C9+ patients with FTD and ALS-FTD phenotypes and remained stable in asymptomatic C9+ sub-
jects. We conclude that diffuse atrophy is a common underlying feature of disease associated with C9orf72mu-
tations across its clinical phenotypes. Ventricular enlargement can be measured over a 6-month time frame,
and appears to be faster in patients with cognitive impairment.
Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Expansion mutations in the C9orf72 gene are one of the most com-
mon causes of familial amyotrophic lateral sclerosis (ALS) and familial
frontotemporal dementia (FTD) in US and European populations
(Renton et al., 2011; DeJesus-Hernandez et al., 2011; Majounie et al.,RS-R, ALS functional rating scale
analysis of variance; bvFTD,
bjects with C9orf72 expansion
ntia rating scale; DTI, diffusion
alse discovery rate correction;
e imaging; sALS, sporadic ALS;
r), devin.bageac@nih.gov
.braun@nih.gov (L.E. Braun),
and.edu (J.Y. Kwan).
ss article under the CC BY license (ht2012). Patients with the C9orf72 mutation can present with a clinical
phenotype of FTD, ALS, or a combination of ALS and FTD symptoms,
even within the same family (Kaivorinne et al., 2013; Hsiung et al.,
2012; Rohrer et al., 2015a). Cross-sectional studies from ALS specialty
clinics found it accounted for 6–8% of non-familial ALS cases, possibly
because the gene is not fully penetrant before the ninth decade
(Majounie et al., 2012), or because a family history of dementia was
not appreciated. Because ALS and FTD patients are typically seen in dif-
ferent specialty clinics, studies of brain imaging have compared C9orf72
ALS and FTD patients to sporadic patients with the same phenotypes.
C9orf72-speciﬁc imaging features of patients with ALS and FTD have
been described in comparison to sporadic patients with the same clini-
cal phenotype (Bede et al., 2013a; Byrne et al., 2012; Rohrer et al.,
2015b;Whitwell et al., 2015; Bocchetta et al., 2016). Among behavioral
variant FTD patients (bvFTD), patients with C9orf72 mutations had a
more diffuse pattern of atrophy than patients with progranulin or
MAPT mutations (Whitwell et al., 2015; Rohrer and Warren, 2011).tp://creativecommons.org/licenses/by/4.0/).
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phy compared to sporadic ALS patients (Bede et al., 2013a; Byrne et
al., 2012).
It is not clear whether a common imaging signature exists across all
C9orf72 gene carriers. Understanding how the imaging ﬁndings differ
between clinical phenotypes, and the relationship between disease pro-
gression and imaging ﬁndings requires a comparison between C9orf72
gene carriers with different phenotypes. Moreover, reports of imaging
differences between asymptomatic C9orf72 gene carriers and non-car-
riers (Rohrer et al., 2015b; Walhout et al., 2015) raise the question
whether symptoms are preceded by subclinical degeneration orwheth-
er differences reﬂect a developmental feature. If imaging changes in
asymptomatic carriers result from ongoing subclinical degeneration,
the changes would be expected to progress over time. In symptomatic
carriers, the relationship between imaging ﬁndings and disease pro-
gression is relevant to the question of whether imaging changes can
be used as a biomarker to follow disease progression in clinical trials
(Cardenas-Blanco et al., 2016; Filippi et al., 2015). The time frame of
clinical trials in ALS tends to be short, typically 6months to one year, be-
cause of the short survival after a diagnosis of ALS is made (Miller et al.,
1999). For an imaging measure to be useful as a biomarker, it should
have measurable changes over 6 months, have good reliability and ef-
fect size, and be correlated to a clinical measure of disease activity. To
better understand the relationship between the C9orf72 genotype and
phenotypes, symptomatic and asymptomatic C9orf72 gene carriers
were recruited for a prospective longitudinal imaging study with clini-
cal evaluations. These participants were not selected for particular clin-
ical presentations in order to permit the spectrum of C9orf72
phenotypes to be explored. Imaging of C9orf72 gene carriers was com-
pared to sporadic ALS patients and healthy controls. The relationship
between imaging changes and disease activity was evaluated longitudi-
nally, as well as in cross-sectional comparisons to sporadic ALS patients
and healthy controls.
2. Methods
2.1. Subjects
2.1.1. C9orf72 participants and controls
Twenty-seven unrelated participants with expansion mutations in
the C9orf72 gene (15 males, 12 females; hereafter referred to as C9+
subjects) and 28 healthy controls (18 males, 10 females) gave written,
informed consent for participation in protocols that were approved by
the NIH Combined Neuroscience Institutional Review Board
(NCT01925196; NCT01517087).
2.1.2. Sporadic ALS cohort
Twenty-two patients with no family history of ALS or FTD (11males,
11 females; hereafter referred to sALS) gave written, informed consent
for an imaging and cognitive study approved by the NINDS Institutional
Review Board (NCT00334516). This cohort was studied prospectively
between 2006 and 2010, prior to the discovery of C9orf72, and the ap-
proved protocol did not include stored DNA. Clinical characteristics
and selected imagingﬁndings from this cohort have been previously de-
scribed (Kwan et al., 2012).
2.2. Diagnostic testing
2.2.1. C9+ subjects
A hexanucleotide repeat expansion of C9orf72was conﬁrmed in all
C9+ subjects by CLIA-certiﬁed clinical testing laboratories. All C9+
subjects were examined by an experienced neurologist (MKF or BT),
and underwent electromyography and cognitive testing to determine
a clinical diagnosis. C9+ subjects meeting the El Escorial criteria-re-
vised for possible, probable, or deﬁnite ALS (Brooks et al., 2000) were
classiﬁed as having a clinical diagnosis of ALS. Cognitive testing fordetermining the clinical diagnosis included the Mattis Dementia Rating
Scale (DRS-2) (Jurica et al., 2001), which tests attention, initiation-per-
severation, conceptualization, construction and memory, and provides
age- and education- scaled scores, and the Frontobehavioral Inventory,
an examiner-delivered 36-item caregiver questionnaire. (Milan et al.,
2008) C9+ subjects meeting the Rascovsky criteria (Rascovsky et al.,
2008) for possible, probable or deﬁnite bvFTDwere classiﬁed as having
a clinical diagnosis of bvFTD. Some C9+ subjects met criteria for both
ALS and bvFTD. As a result, C9+ subjects were classiﬁed into four phe-
notype groups: 1) C9+ asymptomatic, 2) C9+ ALS, 3) C9+ bvFTD and
4) C9+ ALS-FTD.
2.2.2. Healthy controls
All healthy control subjects had a normal neurological examination
and normal scores on the Mini-mental state exam. (Folstein et al.,
1975) None had a family history of ALS or FTD.
2.2.3. Sporadic ALS
A history and neurological exam was carried out by an experienced
neurologist (MKF or JK). All ALS patients underwent diagnostic testing
to conﬁrm that they fulﬁlled the El Escorial criteria for possible, proba-
ble, or deﬁnite ALS (Brooks et al., 2000). Cognitive testing for determin-
ing the clinical diagnosis included the Mattis Dementia Rating Scale
(Jurica et al., 2001) and the Frontal SystemsBehavioral scale Frontal Sys-
tems Behavioral Scale (Stout et al., 2003), which consists of patient and
caregiver interview on current and premorbid symptoms of apathy, dis-
inhibition, and executive dysfunction. None of the sALS patients had
dementia.
2.3. Clinical measures
The severity of motor and executive dysfunction of C9+ subjects
and sALS patients was measured at the baseline visit, and at follow-up
visits of the C9+ subjects, for comparison with imaging ﬁndings.
Motor functionwasmeasured using theALS Functional Rating Scale-Re-
vised (ALSFRS-R), a 48-point scale assessing bulbar, ﬁne motor, gross
motor, and respiratory function (Cedarbaumet al., 1999). Letter ﬂuency,
a measure of executive function, was measured using the ﬂuency sub-
tests of the Delis-Kaplan Executive Function System (Delis et al.,
2004). Letter ﬂuency results are reported here as the total correct num-
ber of words generated in 1 min for 3 letters, either written or orally.
The alternate version of the D-KEFS ﬂuency subtest was used at the 6-
month follow-up of C9+ subjects.
2.4. Imaging methods
2.4.1. Magnetic resonance imaging (MRI) acquisition
2.4.1.1. C9+ subjects and healthy controls. A 3T MRI scanner with a re-
ceive-only, eight-channel head coil (GE HDX, GE Medical Systems, Mil-
waukee, WI) was used for imaging the C9+ subjects and healthy
controls. Two high-resolution T1-weighted sequences (3D fast spoiled
gradient echo sequence, TR+TEvary, TI=450ms, FOV240×240, Res-
olution 256 × 256, 140 slices, 1 mm thickness, voxel =
0.9375 mm × 0.9375 mm × 1 mm) were acquired and averaged at
each time point for FreeSurfer evaluation of volumes and cortical thick-
ness. All patients undergoing scanning had a vital capacity of at least
60% predicted volume; a pulse oximeter was used to monitor patients
with vital capacity below 70%, and all had N90% oxygen saturation
throughout the scanning session.
2.4.1.2. Sporadic ALS cohort.MRI studies of the sALS patients were per-
formed on a 3T scanner (Philips Achieva, Best, the Netherlands) using
a receive-only, eight-channel head coil. For volumetric and thickness
measurements, a high resolution T1 weighted image (3D turbo ﬁeld
echo sequence, TR = 8.6 ms, TE = 3.9 ms, TI = 700 ms, FOV
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0.9375 mm × 0.9375 mm × 1 mm) was obtained. All patients had
vital capacity of 70% or greater.
2.4.2. Image processing: Volumetric and cortical thickness measures
Cortical reconstruction and volumetric segmentation was per-
formed with the FreeSurfer image analysis suite (http://surfer.nmr.
mgh.harvard.edu/). The technical details of these procedures have
been described and validated in prior publications (Fischl et al., 1999;
Fischl et al., 2002; Fischl et al., 2004). Brieﬂy, the processing included
skull stripping, Talairach transformation, optimization of the grey mat-
ter-white matter and grey matter-CSF boundaries, segmentation, and
tessellation (Dale et al., 1999). Images were visually inspected and
scans with errors in segmentation of cortical or CSF surfaces and grey-
white junctions were manually corrected. Atrophied brains were care-
fully inspected for errors. The tessellated surfaces were then inﬂated
and registered to the Desikan-Killiany atlas which parcellates the cere-
bral cortex into 34 regions in each hemisphere based on gyral and sulcal
structures (Desikan et al., 2006). The FreeSurfer longitudinal stream,
which creates an unbiased within-subject template for measuring
changes in cortical thickness over time (http://surfer.nmr.mgh.
harvard.edu/fswiki/LongitudinalProcessing) (Reuter et al., 2012) was
used. Measures of regional cortical thickness were compared between
subgroups and longitudinally. The FreeSurfer QDEC tool was used to
carry out whole-brain vertex-wise comparisons between the baseline
scans of symptomatic C9+ subjects and healthy controls, and between
the C9+ ALS/ALS-FTD patients and sALS patients, including gender as a
covariate. Data were smoothed at 10mm, and p b 0.05with FDR correc-
tion was used as criteria for signiﬁcance.
The volume of ventricles and subcortical structures were also ob-
tained from FreeSurfer. The ventricular volume was obtained by sum-
ming the number of voxels within all ventricles. Volumes were
expressed as a percentage of total intracranial volume (%TIV) to account
for differences in head size for group comparisons. Because FreeSurfer is
not optimized to produce an accuratemeasure of TIV, this valuewas cal-
culated in Statistical ParametricMapping 12 (SPM12,method ofMalone
and colleagues (Malone et al., 2015).
2.4.3. Statistics
Demographic and clinical results are reported as means ± standard
deviations (SD) in tables and text. The Shapiro-Wilk test was used to
test normality of clinical variables. Age, disease duration, and letter ﬂu-
ency scores were normally distributed, and comparisons between
groups were carried out by ANOVA or t-tests. The ALSFRS-R was not
normally distributed. Mann-Whitney or Kruskal Wallis tests were
used for variables that were not normally distributed. ANCOVA was
used to compare volumetric and regional thickness measures, with
age and gender as covariates. Post-hoc testing between C9+ subgroups
and controls was carried out using Dunnett's test for multipleTable 1
Demographics of subject groups, baseline evaluation.
Controls sALS patients C9orf72 subje
Number 28 22 27
Age (years) 52.8 ± 9.1 55.9 ± 11.1 52.2 ± 11.7
Male:Female 18:10 11:11 15:12
Symptom
Duration* (months)
– 27.1 ± 17.4 33.7 ± 24.0
ALSFRS-R 48 40.0 ± 6.9 41.6 ± 7.6
MMSE 29.0 ± 1.2
DRS-2 age/educ
Scaled score
– 8.3 ± 5.1 7.6 ± 4.3
Letter ﬂuency (total for 3 letters) – 35.4 ± 11.8 28.6 ± 14.4
*Excluding asymptomatic carriers; MMSE mini-mental state exam; DRS-2 —Mattis Dementia
a Signiﬁcantly different from C9+ ALS-FTD and bvFTD subgroups.
b Signiﬁcantly different from C9+ asymptomatic subjects.comparisons or Dunn's correction for nonparametric testing. Pearson's
r was used to assess correlations. A repeated measures ANOVA was
used to assess longitudinal changes, adjusting for age and gender as co-
variates. Statistics were calculated with SPSS v.23 (IBM SPSS Statistics).
Signiﬁcance was deﬁned as p b 0.05, corrected for multiple
comparisons. G*Power v 3.1 (http://www.gpower.hhu.de/en.html,
accessed 8/25/2016) was used for power and sample size calculations.
3. Results
3.1. Clinical demographics
3.1.1. Demographics of groups
There was no difference in age between the C9+, sALS, and healthy
control groups. The ratio of men to women was similar in the groups,
with slightly more men than women in the C9+ and control groups
(Table 1). Symptom duration and ALSFRS-R did not differ between
sALS and symptomatic C9+ patients.
3.1.2. C9+ subgroup demographics
At the baseline visit, seven C9+ subjectswere asymptomatic, eleven
had C9+ ALS, three had C9+ bvFTD, and six had C9+ ALS-FTD (Table
1). In the C9+ subgroups, asymptomatic subjects were younger than
C9+ subjects with ALS-FTD (p=0.013). In symptomatic C9+ subjects,
cognitive-behavioral changeswere theﬁrst symptom in six patients and
amotor deﬁcit was the ﬁrst symptom in the other 14, including ﬁve pa-
tients with bulbar-onset ALS. Age of symptom onset and disease dura-
tion did not differ among subgroups of symptomatic C9+ patients.
Cognitive testing showed that letter ﬂuency and the DRS-2 age- and ed-
ucation-scaled score were not signiﬁcantly different between the sALS
and the C9+ groups as a whole (t-test, p = 0.1273, p = 0.6380).
Asymptomatic C9+ subjects had signiﬁcantly better scores than C9+
ALS-FTD and bvFTD patients, but were not different from C9+ ALS
subjects.
Nineteen C9+ subjects returned for a 6-month follow-up (mean=
5.7 ± 0.7 months), and seven returned for an 18-month follow-up. The
6-month follow-up cohort consisted of ﬁve C9+ asymptomatic, six
C9+ ALS, ﬁve C9+ ALS-FTD, and three C9+ bvFTD subjects. Twenty-
three of the 28 healthy controls had two imaging sessions and seven-
teen had three imaging sessions at various intervals. Control scans
were selected with a mean interval of 5.6 ± 4.3 months to compare
with the 6-month follow-up scans of C9+ subjects.
3.2. Volumetric measures
3.2.1. Baseline differences in ventricular volume
At the baseline visit, the C9+ subject group as awhole had evidence
of brain atrophy, with increased ventricular volume compared to con-
trols (Fig. 1A). The ventricular volume of the sALS group did not differcts (all) C9+ diagnosis subgroups
Asymptomatic ALS ALS-FTD bvFTD
7 11 6 3
41.2 ± 11a 52.3 ± 8.8 60.8 ± 10.2 60.6 ± 5.1
1:6 5:6 6:0 3:0
– 30.7 ± 23.9 33.7 ± 29.3 29.4 ± 26.5
48 36.2 ± 8.4b 41.8 ± 5.26b 46.3 ± 2.9
10.7 ± 2.9a 8.6 ± 3.6 3.8 ± 3.8 2.3 ± 2.3
42.3 ± 12.4a 30.0 ± 11.2 13.8 ± 3.0 16.0 ± 4.4
Rating Scale, scaled for age and education, normal mean = 10; within C9+ subgroups.
Fig. 1.Ventricular volumes expressed as the percent of Total Intracranial Volume (TIV) at baseline (A–C) and longitudinally (D–F). A) At baseline, C9+ subject group had larger ventricles
than healthy controls (HC; *p b 0.05). Sporadic ALS (sALS) did not differ from controls. B)Within the C9+ subgroups, C9+ALS-FTD patients had larger ventricles than asymptomatic C9+
carriers (Asymp) and HC (*p b 0.05). C) Ventricular volume increasedwith disease duration in C9+ subjects (ﬁlled circles, solid lines) and sALS (open squares, dashed line) with a similar
slope, but C9+ had larger ventricles, adjusted for age, compared to sALS and HC. D) Change in ventricular volume over 6 months in C9+ subjects. E) Rate of ventricular enlargement per
month, calculated from baseline to 6 month-follow-up of 19 C9+ subjects and 23 HC (individual values, line indicates group mean). F) Ventricular volumes all scans C9+ subjects,
including longitudinal scans for asymptomatic C9+ (ﬁlled circles), C9+ ALS (open circles), C9+ bvFTD (open triangles) and C9+ ALS-FTD (ﬁlled squares) plotted by symptom duration.
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FTD had larger ventricles than C9+ asymptomatic subjects and healthy
controls (Fig. 1B). In all groups, age was correlated with ventricular vol-
ume, with no difference in slope between groups, although C9+ sub-
jects had a signiﬁcant intercept shift relative to controls and sALS,
indicating greater atrophy for age. Ventricular volumewas also correlat-
edwith symptomduration,with a signiﬁcant shift in the intercept in the
C9+ group (Fig. 1C). There was no signiﬁcant effect of gender on ven-
tricular volume, whichwas expressed as percentage of total intracranial
volume.
3.2.2. Longitudinal changes in ventricular volume
The ventricular volume increased on average by 3.5 ml in the symp-
tomatic C9+ subjects in the 6-month interval between scans (Fig. 1D).
The age-adjusted rate of ventricular enlargement was greater in C9+
subjects as a whole than controls, with a relatively broad range (Fig.
1E). Post-hoc statistics identiﬁed only the C9+ bvFTD and C9+ ALS-
FTD subgroups as having greater ventricular enlargement than healthycontrols over 6months. In asymptomatic C9+ subjects, ventricular vol-
ume was relatively stable, including over longer longitudinal intervals,
whereas symptomatic C9+ patients had increasing ventricular vol-
umes, even among the symptomatic patients with long symptom dura-
tion (Fig. 1F).3.2.3. Volumes of subcortical structures
In scans obtained at the baseline visit, the volume of the thalamus
was smaller in C9+ subjects compared to controls and sALS patients.
Both right and left sides of the thalamus had smaller volumes. Post-
hoc testing showed that the thalamic volumes of C9+ bvFTD and
C9+ ALS-FTD subgroups were less than controls (Table 2). There was
no signiﬁcant difference in the volume of the cerebellum, caudate, puta-
men, or pallidum among the C9+, sALS, and control groups at baseline.
Over the 6-month follow-up interval, C9+ subjects had signiﬁcant vol-
ume loss in the thalamus but not in the other subcortical regions com-
pared to controls.
Table 2
Volume of subcortical structures.
Healthy controls sALS C9+ (all) C9+ subtypes
Asymp. ALS bvFTD ALS-FTD
Cerebellum 8.65 ± 0.77 8.28 ± 0.91 8.46 ± 0.91 9.22 ± 0.74 8.64 ± 0.72 7.94 ± 0.36 7.53 ± 0.65
Thalamus 0.98 ± 0.11 0.91 ± 0.10 0.88 ± 0.12a 1.01 ± 0.08 0.90 ± 0.07 0.76 ± 0.09a 0.77 ± 0.09a
Caudate 0.50 ± 0.06 0.51 ± 0.06 0.47 ± 0.08 0.49 ± 0.07 0.52 ± 0.07 0.38 ± 0.07 0.41 ± 0.05
Putamen 0.72 ± 0.10 0.70 ± 0.11 0.67 ± 0.15 0.78 ± 0.09 0.72 ± 0.11 0.51 ± 0.12 0.53 ± 0.10
Pallidum 0.20 ± 0.03 0.21 ± 0.03 0.19 ± 0.04 0.21 ± 0.03 0.21 ± 0.03 0.14 ± 0.02 0.15 ± 0.03
Volumes are expressed as % of total intracranial volumes. sALS = sporadic ALS, Asymp = C9+ asymptomatic carriers.
a Less than controls, p b 0.05, Dunnett's test, corrected for multiple comparisons.
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The volume of cortical white matter of the right and left hemi-
spheres was less for C9+ subjects than sALS patients and controls
(left cortex p = 0.014; right cortex p = 0.020), with age included as a
covariate. Gender and disease duration were not signiﬁcant covariates.
Dunnett's test showed that among the C9+ subgroups, the C9+ ALS-
FTD and FTD white matter volumes differed from that of sALS patients
(p b 0.05). The white matter volume of sALS patients did not differ
from controls (left, p = 0.843; right, p = 0.891).
3.3. Cortical thickness
3.3.1. Vertex-wise comparison between groups
A whole-brain comparison of cortical thickness between the 20
symptomatic C9+ subjects versus the 28 healthy controls showed a
widespread, patchy distribution of cortical thinning (Fig. 2 A). Clusters
of thinning were particularly prominent in the superior and medial
frontal cortex and temporal poles bilaterally. Thinning also occurred in
the cuneus, posterior cingulate and small scattered cortical regions.
Areas of sparing included the occipital pole and the anterior andmiddle
portions of the cingulate gyrus. Therewasnodifference in cortical thick-
ness between C9+ asymptomatic subjects and controls. When the
group of 17 C9+ ALS and ALS-FTD patients were compared to the
group of 22 sALS patients, C9+ ALS patients had thinner cortex in
many areas, particularly in frontal and temporal regions (Fig. 2 B). Inter-
estingly, the motor cortex was less thin (red, yellow) in C9+ ALS and
ALS-FTD patients than in sALS patients.
3.3.2. Regional differences in cortical thickness
The mean cortical thickness of both left and right hemispheres was
less in the C9+ subject group as a whole compared to healthy controls
and to sALS patients in the baseline scans (Table 3). Among the C9+Fig. 2. Regions of cortical thinning in whole-brain analyses of C9+ subjects compared to other
thinning, with broad swaths of thinning in frontal and temporal regions compared to healthy c
thinning with a frontal predominance compared to sporadic ALS patients (n = 22). In contra
view(yellow-orange areas). Vertex-wise comparisonusing FreeSurfer. (Fischl andDale, 2000) Tsubgroups, the mean cortical thickness was less in the C9+ ALS-FTD
and C9+ ALS patients compared to controls. To determine which corti-
cal areasmost accounted for differences in themean hemispheric thick-
ness, a multivariate analysis was carried out on the 34 gyral regions of
each hemisphere (Desikan et al., 2006) including age and gender as co-
variates. As predicted from the whole-brain vertex-wise analysis, the
C9+ group had thinning in several non-motor regions compared to
sALS patients and controls, particularly frontal regions. Regionswith dif-
ferences between groups are indicated by letters in Table 3. Both sALS
and C9+ groups had thinning of the right precentral gyrus. The thick-
ness of the left precentral and paracentral gyri, the insula, and the cingu-
late cortex was not signiﬁcantly different between C9+, sALS, and
control groups.
Cortical thickness of the regions that differed signiﬁcantly from con-
trols were compared between the subgroups of C9+ subjects and the
sALS patients to look for differences associated with genotype. C9+
ALS patients had signiﬁcant thinning of the superior frontal and
orbitofrontal cortex bilaterally compared to sALS patients (Dunnett's
test; p b 0.05). These regions were also thinner in the C9+ ALS-FTD
and C9+ FTD subgroups than in sALS patients. The C9+ ALS-FTD and
C9+ FTD subgroups also had thinning of several frontal and temporal
regions, of which several were adjacent, compared to sALS patients
(Supplemental Table 1). Asymptomatic C9+ subjects did not have
any regions of thinning compared to sALS patients.
3.3.3. Longitudinal changes in thickness
Changes in regional cortical thickness between the baseline and 6-
month follow-up scan were compared for the 19 C9+ subjects and
the group of 23 healthy controls. The C9+ subject group included 5
asymptomatic subjects, 6 C9+ ALS, 5 C9+ ALS-FTD, and 3
C9 + bvFTD patients. Although the inter-scan intervals of C9+ group
and control group were matched between groups, rates of thinning
were analyzed to adjust for variation in inter-scan intervals. The rategroups are indicated in blue. A) Symptomatic C9+ subjects (n = 20) have diffuse patchy
ontrols (n = 28). B) C9+ patients with ALS or ALS-FTD (n = 17) have patchy regions of
st, sALS patients have thinner motor cortex than C9+ patients, best seen in this inﬂated
he color scale indicates thenegative log of the p values (thresholdp=0.05, FDR corrected).
Table 3
Thickness of selected cortical regions at the baseline scan.
Left hemisphere Right hemisphere
Healthy controls
(n = 28)
C9+ subjects (all)
(n = 27)
Sporadic ALS
(n = 22)
Sig Healthy controls
(n = 28)
C9+ subjects (all)
(n = 27)
Sporadic ALS
(n = 22)
Sig
Mean thickness (hemisphere) 2.45 ± 0.09 2.33 ± 0.16 2.44 ± 0.11 A, B 2.44 ± 0.09 2.33 ± 0.17 2.43 ± 0.12 A, B
Precentral 2.56 ± 0.17 2.44± 0.21 2.40± 0.16 2.55± 0.16 2.40± 0.23 2.34± 0.19 B, C
Paracentral 2.44 ± 0.14 2.32± 0.18 2.37± 0.23 2.43± 0.14 2.28± 0.18 2.39± 0.20
Postcentral 2.12 ± 0.12 2.05± 0.16 1.99± 0.13 2.10± 0.14 2.01± 0.21 1.97± 0.16
Insula 2.95± 0.16 2.88± 0.21 2.94± 0.16 2.91± 0.15 2.83± 0.21 2.92± 0.18
Lateral orbitofrontal 2.45± 0.12 2.38± 0.21 2.60± 0.12 A 2.41± 0.11 2.34± 0.18 2.49± 0.16 A, C
Medial orbitofrontal 2.37± 0.12 2.35± 0.21 2.35± 0.19 2.30± 0.12 2.26± 0.18 2.48± 0.17 A
Rostral middle frontal 2.30± 0.09 2.18± 0.18 2.32± 0.10 A, B 2.25± 0.09 2.16± 0.17 2.32± 0.13 A
Superior frontal 2.59± 0.09 2.47± 0.23 2.70± 0.13 A 2.56± 0.10 2.42± 0.19 2.68± 0.15 A, B
Caudal middle frontal 2.47 ± 0.09 2.35 ± 0.19 2.49 ± 0.12 A, B 2.45 ± 0.11 2.38 ± 0.19 2.44 ± 0.15
Lateral occipital 2.20± 0.11 2.07± 0.14 2.20± 0.15 2.24± 0.13 2.14± 0.15 2.27± 0.14 A
Fusiform 2.74± 0.14 2.61± 0.21 2.65± 0.15 2.73± 0.15 2.58± 0.21 2.64± 0.14 B
Middle temporal 2.84± 0.16 2.72± 0.22 2.84± 0.20 2.80± 0.14 2.71± 0.20 2.88± 0.19 A
Inferior parietal 2.42 ± 0.10 2.30 ± 0.16 2.45 ± 0.16 A, B 2.42 ± 0.13 2.32 ± 0.18 2.43 ± 0.14
Means ± SD. Sig = signiﬁcant differences, corrected for age and multiple comparisons p b 0.05.
A: C9+ b sALS, B: C9+ b HC, C: sALS b HC.
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group as a whole or the C9+ subgroups.
3.4. Clinical correlations
3.4.1. Cortical thickness
Cortical thickness and letter ﬂuency correlated with age, although
the ALSFRS-R score did not. Therefore, age was included as a covariate,
and partial correlations were calculated. There was a weak but signiﬁ-
cant correlation between the ALSFRS-R of the C9+ and sALS groups
with the thickness of the precentral gyri bilaterally (right side r =
0.389, p = 0.007; left side r = 0.394, p = 0.006). The ALSFRS-R was
not signiﬁcantly correlated with thickness of other cortical regions. In
contrast, the letter ﬂuency score was correlated with the age-adjusted
thickness of many cortical areas, with moderately strong correlations
with the caudal middle frontal gyrus and pars opercularis bilaterally,
the right pars orbitalis, and left entorhinal cortex (r = 0.5–0.7). Several
other frontal, temporal, and parietal regions exhibited weaker correla-
tions (r = 0.3–0.5) as did the precentral and paracentral gyri (Supple-
mental Table 2).
3.4.2. Volumes
The ALSFRS-R scores were not correlatedwith the baseline ventricu-
lar volume or volumes of subcortical structures of sALS and C9+ sub-
jects. There was a weak correlation between the longitudinal change
in ALSFRS-R and the change in ventricular volume (r = 0.489, p =
0.034) but signiﬁcance did not survive correction for age. At baseline,
letter ﬂuency scores had a weak negative correlation with ventricular
volume (r =−0.352, p = 0.028) and a weak positive correlation with
the volume of the thalamus (r = 0.446, p = 0.004) adjusted for age
and gender.
3.5. Reproducibility of imaging measures with repeat scanning
In healthy controls, imaging measures of ventricular and all subcor-
tical volumes were strongly correlated between scans at the 2 time
points (Pearson's correlation coefﬁcients: ventricular volume, r =
0.997; thalamus, r = 0.994; cerebellum, r = 0.929; caudate r = 0.986;
putamen r=0.971, pallidum0.932. All p values b 0.0001). Themeasure
of ventricular volume, expressed as %TIV, was highly reproducible in the
two scans (Lin's concordance correlation coefﬁcient (ρc) = 0.9967).
These data show that ventricular volume can be reliablymeasured in re-
peat scans from healthy controls who do not have ongoing degenera-
tion. The healthy control group had minimal change in ventricular
volume over 6 months (mean difference of −0.22 ml/6-month), anorder of magnitude less than symptomatic C9+ subjects. Although
this ﬁndingmay seem encouraging that themeasurement of ventricular
volume is sufﬁciently reliable to follow over time as a biomarker of pro-
gression, a power calculation based on data from the 14 symptomatic
subjects with longitudinal imaging shows that relatively large sample
sizes would be needed to detect the effects of an intervention between
treated and untreated groups of C9+ symptomatic subjects. Using the
measures of ventricular volume change in symptomatic C9+ subjects
in this study, Table 4 shows the sample and effect sizes calculated for
hypothetical interventions that reduce ventricular volume loss by 20–
50% compared to no treatment. Detecting even a medium effect
(0.5 b d N 0.3), would require sample sizes of 50 or more patients per
group. This reﬂects, in part, the large variability between C9+ subjects.
Regional measures of cortical thickness were also reproducible be-
tween the 2 scans, although correlations were weaker than for volume
measures. For the 34 cortical regions of each hemisphere, thickness of
each region at the two time points was strongly correlated and signiﬁ-
cant (r N 0.7, p b 0.0001), except for two regions, the right precuneus
and rightmedial orbitofrontal cortex. For the other areas, correlation co-
efﬁcients ranged from 0.748 to 0.966. Eighteen regions of the left hemi-
sphere and 14 regions of the right hemisphere had very strong
correlations (r N 0.9) between the two time points, including regions
that would be of particular interest, such the precentral gyrus and sev-
eral frontal and temporal regions (Supplemental Table 3).4. Discussion
Persons with an expansion mutation of the C9orf72 gene had diffuse
brain atrophy compared to healthy controls and sporadic ALS patients.
Evidence of cortical and subcortical atrophy was seen in symptomatic
C9orf72 carriers, regardless of whether their clinical phenotype was
ALS, FTD, or ALS-FTD. Among the C9+ phenotypes, atrophy was most
severe in C9+ patients with clinical features of bvFTD. However, even
C9+ ALS patients without dementia had regions of thinning compared
to sporadic ALS patients. Atrophy was the common underlying feature
of disease associatedwith C9orf72mutations. Becausewe did not detect
signiﬁcant atrophy in the asymptomatic C9+ subjects in this study, it is
less likely to reﬂect a developmentally acquired condition. Over follow-
up intervals up to 18 months, ventricular volumes remained stable in
the clinically-stable asymptomatic C9+ subjects, whereas progressive
ventricular enlargement was seen in symptomatic C9+ subjects. For
this reason, we suggest that atrophy is directly associated with active
disease, and that longitudinal imaging may reveal progression of
disease.
Table 4
Sample sizes calculated to detect a 6-month difference in ventricular volume between a group of treated and untreated symptomatic C9+ subjects.
6-month mean ventricular
volume change (ml)
Effect size
(Cohen's d)
Sample per group
power = 0.8
Sample per group
power = 0.9
Current data: Symptomatic C9+ −3.5
20% Improvement −2.78 0.26 232 310
30% Improvement −2.43 0.41 95 126
40% Improvement −2.08 0.57 49 65
50% Improvement −1.74 0.74 30 39
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the hypothesis that degeneration spreads from one region to another in
a disease-speciﬁc pattern: progressing from rostral to caudal from the
frontal cortex in bvFTD (Brettschneider et al., 2014; Kim et al., 2012)
and spreading centrifugally from the motor cortex in sporadic ALS
(Braak et al., 2013). Cross-sectional imaging studies of patients with
sporadic ALS (Agosta et al., 2012; Roccatagliata et al., 2009; Verstraete
et al., 2012; Kassubek et al., 2014) and sporadic FTD (Mahoney et al.,
2012; Rohrer and Rosen, 2013; Huey et al., 2009), comparing patients
at different stages of disease, have largely been consistent with these
pathological hypotheses. A longitudinal study of sporadic ALS patients
was also consistent,ﬁnding local greymatter loss inmotor cortex earlier
than in regions receiving motor cortical inputs, such as the frontal cor-
tex and basal ganglia (Menke et al., 2014). Disease-speciﬁc patterns
were not evident in the C9+ patients in this study. The C9+ clinical
phenotypes were not differentiated by localized thinning or atrophy,
but had thinning across many scattered cortical regions. In most pa-
tients, right and left sides were strongly correlated, without lateralized
atrophy, as occurs in FTD patients with mutations in the GRN gene
(Rohrer et al., 2015a). These ﬁndings suggesting a more diffuse spread
of degeneration in C9orf72 related diseases.
The ﬁndings of atrophy in symptomatic patients agree with earlier
studies that compared groups of patients with sporadic ALS or FTD to
C9orf72 patients with the same phenotype (Bede et al., 2013a; Byrne
et al., 2012; Rohrer et al., 2015b; Whitwell et al., 2015). As in previous
studies, cognitive impairment was associated with subcortical atrophy,
notably thalamic atrophy, in C9orf72 ALS patients (Bede et al., 2013a;
Bede et al., 2013b). The C9+ subjects with ALS-FTD and bvFTD in this
study had smaller thalamic volumes, consistent with reports from
other FTD patient populations (Rohrer et al., 2015a), as well as patchy
cortical thinning. Letter ﬂuency, the measure of executive function
used in this study, has been shown to activate the left temporal lobe
and several frontal regions in task-based fMRI (Cook et al., 2014;
Abrahams et al., 2004). However, we found that letter ﬂuency scores
were correlated with cortical thinning in many regions, including the
motor cortex. Thismay reﬂect the ease of disrupting cognitive networks
for searching and retrieving words by letter. This study and others
(Machts et al., 2015) highlight the importance of characterizing both
motor and cognitive-behavioral function in patients with C9orf72muta-
tions. In this study, inwhich all C9+subjects underwent the same testing
formotor and cognitive function, a third of the C9+ subjects in this study
met clinical criteria for both ALS and bvFTD. It is unknown whether the
proportion of phenotypes in this sample is representative of their propor-
tions in the population of C9orf72mutation carriers. Population-based
studies fully characterizing motor and cognitive symptoms would be
needed to determine the relative proportions of each phenotype among
the population of C9orf72 carriers. In one large US ALS clinic, 61 of 781
ALS patients carried the C9orf72 mutation (7.8%), and of these nine
(14.8%) had comorbid FTD (Umoh et al., 2016). We had a higher propor-
tion of co-morbid C9+ ALS and FTD in our study. This may reﬂect that
patients whose symptoms begin with cognitive-behavioral symptoms,
and later develop motor symptoms, are not represented in an ALS clinic
population. Recruitment for this study reached out to memory clinics as
well as ALS specialty clinics for referral of patientswithC9orf72mutations.
We recognize as well that the patients in this study represent a selected
group, willing to travel to participate in research.The longitudinal symptomatic C9+ patients showed considerable
variability in clinical progression, with symptom durations ranging
from 1month to 88months at the time of enrollment. A relatively indo-
lent course prior to enrollment was present in one C9+ ALS patient as
well as in several C9+ ALS-FTD patients whose ﬁrst symptomwas cog-
nitive impairment. One limitation in evaluating the relationship be-
tween imaging ﬁndings and symptom duration was difﬁculty in
pinpointing the onset of cognitive-behavioral changes. Additionally,
some C9+ ALS patients who did not meet criteria for bvFTD may have
had milder degrees of cognitive and behavioral impairment. The small
sample size did not allow further gradations of cognitive impairment.
Drop-out of rapidly progressing patients from 6-month follow-up
scans is another potential source of bias. A 6-month follow-up interval
was selected because it is a time span over which ALS patients deterio-
rate, and is also a typical time span for interventional clinical trials.
However, because some rapidly progressing ALS patients were unable
to return for scanning, the longitudinal cohort was enriched for asymp-
tomatic C9+ and less impaired patients. More severely affected pa-
tients may have greater imaging changes, and thus the changes
reported here may be an underestimate.
Understanding whether imaging provides genotype- or phenotype-
speciﬁc signatures, and the temporal relationship between imaging
ﬁndings and clinical symptoms, is important to understand in a familial
disease. Familial motor neuron disorders present an opportunity to
identify imaging changes associated with early disease activity in pre-
symptomatic gene carriers (Benatar and Wuu, 2012; Turner and
Benatar, 2015). Studies in familial FTD patients identiﬁed changes in
asymptomatic carriers who were 5–10 years younger than the typical
age of disease onset in their family members (Rohrer et al., 2015b;
Dopper et al., 2014). Similarly, metabolic changes have been identiﬁed
in the spinal cord of asymptomatic carriers of the SOD1A mutation
(Carew et al., 2011a). A study of asymptomatic C9orf72 gene carriers
and non-carrierswithin a single large family found greymatter thinning
in several cortical regions (Walhout et al., 2015). It is unclear whether
genotype-speciﬁc imaging ﬁndings herald the onset of clinical disease.
Although our study was unable to identify structural changes in asymp-
tomatic carriers compared to healthy controls, longitudinal follow-up is
needed to understand whether slowly developing changes occur, and
whether imaging differences predict the development of clinical
symptoms.
In this study, we analyzed ventricular volume as a candidate bio-
marker for a number of reasons: enlarged ventricles are a visible abnor-
mality seen in clinical scans, the scan-rescan reproducibility of
ventricular volume with our methods was excellent for healthy con-
trols, and ventricular size can be measured using a variety of different
software programs. Moreover, ventricular enlargement may pick up at-
rophy from patchy cortical thinning, whitematter atrophy, or mild sub-
cortical atrophy when affected regions vary between individuals. Our
ﬁnding of ventricular enlargement in the symptomatic C9+ group
over 6 months is consistent with previous longitudinal studies in spo-
radic ALS that detected grey matter loss over a 6-month (Menke et al.,
2014) or 1-year (Kwan et al., 2012) interval as well as a study that
found annualized rates of atrophy in the range of 2–3% in bvFTD groups
(Whitwell et al., 2015). While detecting changes in C9+ symptomatic
patients over 6months offers encouragement that imagingmay be use-
ful to follow disease progression in individuals within the time window
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quire large sample sizes if ventricular enlargement were to be used as a
sole biomarker. The variability might be improved with a better under-
standing of factors contributing to individual differences in disease
onset and progression. Regardless, the change in ventricular volume
may be useful to create a composite marker in combination with other
measures. These could include other imaging modalities, such as diffu-
sion imaging (Cardenas-Blanco et al., 2016; Muller et al., 2016) or spec-
troscopy (Carew et al., 2011b; Stagg et al., 2013), or bioﬂuid markers
such as the C9orf72 repeat-associated dipeptide (Su et al., 2014).
Why C9orf72mutations cause different phenotypes, evenwithin the
same family (Byrne et al., 2012) is not clear. Different phenotypes could
result from distinct disease initiation sites that spread through synaptic
connections, or frompatient-speciﬁc vulnerabilities of different neurons
to themolecular pathways disturbed by the C9orf72mutation (Donnelly
et al., 2013; Ling et al., 2013). Alternatively, C9orf72mutations could be
causing degeneration randomly in individual neurons throughout the
brain, such that clinical symptoms become evident when brain net-
works fail (Schmidt et al., 2016; Schmidt et al., 2014; Lee et al., 2014).
Whether the phenotypic variability of subjects with the C9orf72muta-
tion can be linked to selective vulnerability or patterns of spread
through axonal networks, and how these might interact with genetic
(van Blitterswijk et al., 2014) and epigenetic (McMillan et al., 2015)
modiﬁers of clinical phenotypes of C9orf72, will need to be assessed in
C9+ subjects scanned before and soon after onset of clinical symptoms.
Studies of a larger numbers of C9orf72 carriers imaged before and after
the onset of symptoms are needed to test whether disease spreads
through networks or occurs randomly across the brain.
5. Conclusion
Symptomatic carriers of the C9orf72 expansion mutation exhibit
more brain atrophy than healthy controls of a similar age. Atrophy oc-
curs regardless ofwhether carriers presentwith anALS or bvFTD clinical
phenotype, although atrophy is greater in patients with cognitive-be-
havioral impairment. Ventricular enlargement and thalamic atrophy
can be detected in groups of symptomatic patients over a 6-month
interval.
Supplementary data to this article can be found online at doi:10.
1016/j.nicl.2016.10.014.
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